Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Hoenigl, M; Raggam, RB; Salzer, HJ; Valentin, T; Valentin, A; Zollner-Schwetz, I; Strohmeier, AT; Seeber, K; Wölfler, A; Sill, H; Krause, R.
Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies.
Int J Antimicrob Agents. 2012; 39(6):510-513
Doi: 10.1016/j.ijantimicag.2012.02.002
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hönigl Martin
- Krause Robert
- Co-Autor*innen der Med Uni Graz
- Raggam Reinhard Bernd
- Salzer Helmut J. F.
- Sill Heinz
- Valentin Thomas
- Wölfler Albert
- Zollner-Schwetz Ines
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Posaconazole (PCZ) is a triazole antifungal agent that has broad activity against pathogenic fungi and is increasingly used for prophylaxis and treatment of invasive mould infections (IMIs). PCZ is only available as an oral formulation, with varying absorption from the gastrointestinal tract. However, reports correlating PCZ plasma concentrations (PPCs) with breakthrough IMIs are rare. In this study, PPCs were analysed in a prospective, observational, single-centre study and the correlation of PPCs with breakthrough IMIs in patients with haematological malignancies was evaluated. Risk factors associated with low PPCs were further evaluated. A total of 109 PPCs were measured in 34 cases receiving PCZ prophylaxis (n=31) or treatment (n=3). Levels below the target of 0.5 μg/mL were detected in 24 (71%) of the 34 cases; in 15 (63%) of these 24 cases concentrations were found to be <0.20 μg/mL. Three patients receiving PCZ prophylaxis met the criteria of breakthrough infection. Notably, prior to development of IMI, PPCs were below the target in all three individuals. Associated risk factors for insufficient PPCs varied from previous reports. In conclusion, these data demonstrate that therapeutic drug monitoring of PCZ is mandatory in all patients with haematological malignancies as low PPCs are common and may be associated with development of IMIs.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antifungal Agents - blood
- Aspergillosis - drug therapy
- Chemoprevention -
- Drug Monitoring -
- Female -
- Hematologic Neoplasms - complications
- Humans -
- Male -
- Middle Aged -
- Mycoses - blood
- Risk Factors -
- Triazoles - blood
- Young Adult -
- Find related publications in this database (Keywords)
- Posaconazole plasma concentration
- Antifungal prophylaxis
- Antifungal therapy
- Haematological malignancy
- Therapeutic drug monitoring